Top & Current
Tue, August 6, 2024
[ Tue, Aug 06th 2024
] - WOPRAI
Tue, July 23, 2024
[ Tue, Jul 23rd 2024
] - WOPRAI
Wed, August 2, 2023
[ Wed, Aug 02nd 2023
] - WOPRAI
Wed, June 28, 2023
[ Wed, Jun 28th 2023
] - WOPRAI
Tue, May 2, 2023
[ Tue, May 02nd 2023
] - WOPRAI
Thu, February 16, 2023
[ Thu, Feb 16th 2023
] - WOPRAI
Fri, October 28, 2022
[ Fri, Oct 28th 2022
] - WOPRAI
Thu, July 21, 2022
[ Thu, Jul 21st 2022
] - WOPRAI
Mon, June 13, 2022
[ Mon, Jun 13th 2022
] - WOPRAI
Tue, November 23, 2021
Thu, October 21, 2021
[ Thu, Oct 21st 2021
] - WOPRAI
Mon, November 9, 2020
[ Mon, Nov 09th 2020
] - WOPRAI
Tue, August 18, 2020
Wed, October 23, 2019
[ Wed, Oct 23rd 2019
] - WOPRAI
Wed, July 19, 2017
Phil Nadeau Maintained (BMRN) at Strong Buy with Decreased Target to $120 on, Aug 6th, 2024
Phil Nadeau of TD Cowen, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Decreased Target from $125 to $120 on, Aug 6th, 2024.
Phil has made no other calls on BMRN in the last 4 months.
There are 6 other peers that have a rating on BMRN. Out of the 6 peers that are also analyzing BMRN, 3 agree with Phil's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Whitney Ijem of "Canaccord Genuity" Maintained at Hold and Held Target at $89 on, Thursday, July 25th, 2024
- Joel Beatty of "Baird" Downgraded from Buy to Hold and Decreased Target to $72 on, Friday, May 17th, 2024
- David Lebovitz of "Citigroup" Maintained at Hold with Decreased Target to $91 on, Thursday, April 25th, 2024
These are the ratings of the 3 analyists that currently disagree with Phil
- Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $110 on, Monday, August 5th, 2024
- Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $115 on, Thursday, June 27th, 2024
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $112 on, Friday, April 26th, 2024